Navigation Links
Chroma Announces Positive Phase I Efficacy Data for Novel Cancer Therapy CHR-2797
Date:12/13/2007

+44 (0)20 7404 5959

Justine McIlroy

About aminopeptidases and CHR-2797

Aminopeptidases are a family of intracellular enzymes involved in the supply of amino acids that are essential for cell growth. Inhibition of aminopeptidases has been shown to halt cell growth or cause apoptosis (cell death) in a large number of cancer cell lines. Conversely, normal (non-tumour) cell lines have been shown to be insensitive to aminopeptidase inhibition. CHR-2797 is a potent inhibitor of aminopeptidases that has demonstrated strong preclinical efficacy as monotherapy and has also been shown to strongly synergise with a number of leading cancer therapies in a range of cancer cells.

About Chroma Therapeutics

Chroma Therapeutics, based in Oxford (UK), is a drug discovery and development company focused in the fields of oncology and inflammatory disorders. Chroma is building a broad pipeline of first- or best-in-class treatments utilising its expertise in chromatin biology and its novel intracellular accumulation technologies, which include the ability to selectively target drugs to macrophages. Chroma is backed by a number of leading specialist investors, including Abingworth, Essex Woodlands, Gilde, Nomura Phase4 and The Wellcome Trust.

More information about Chroma can be found at http://www.chromatherapeutics.com.


'/>"/>
SOURCE Chroma Therapeutics Limited
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... DUBLIN , Nov. 26, 2014  Perrigo Company ... leading global provider of "Quality Affordable Healthcare Products®," today ... offering relating to the sale of 6,809,210 ordinary shares ... including the full exercise of the option to purchase ... Morgan Securities LLC and Barclays Capital Inc., as representatives ...
(Date:11/26/2014)... , Nov. 26, 2014   Regulus Therapeutics Inc ... leading the discovery and development of innovative medicines targeting ... Ph.D., President and CEO of Regulus, will present a ... Jaffray Healthcare Conference at the New York Palace Hotel ... The presentation will be webcast at the time of ...
(Date:11/26/2014)... Scott Steiger lives in St. ... an engineer for the past 20 years, he,s traveled extensively and ... He,s been to six of the seven continents. Travel is a ... http://photos.prnewswire.com/prnh/20141126/161076 Photo - http://photos.prnewswire.com/prnh/20141126/161077 So ... pretty good idea of what,s required. His latest creation ...
Breaking Medicine Technology:Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 3Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 4Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 2Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 3Steiger Has Created the First Pill Case Specifically Designed For Travel 2
... by experts to be important for cervical cancer ... data from an,extended follow-up study show that GlaxoSmithKline ... generates sustained high levels of,neutralizing antibodies against the ... up to 6.4 years. This is the longest,duration ...
... American Society of Hypertension,s Twenty-Third ... Annual Scientific Meeting - A cumulative ... a regimen of BENICAR(R) (olmesartan medoxomil), and BENICAR HCT(R) (olmesartan ... normotension (< 120/80 mm Hg) (placebo:1.4%)., - Eight out of ...
Cached Medicine Technology:CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 2CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 3CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 4CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 5CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 6New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 2New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 3New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 4New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 5New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 6New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 7
(Date:11/28/2014)... An inventor and dental assistant from Kent, Wash., ... and it was almost impossible to reach. "This gave me ... , The patent-pending Access Light allows for easier use of ... the mouth, as well as avoids harm to the lips, ... use and clean, it also helps prevent cross-contamination. , The ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 A newly ... provides an overview of the influenza virus that will soon ... season. , The article begins with a brief explanation ... its symptoms. It reminds families that children under the age ... suffering from chronic diseases, such as heart and lung diseases, ...
(Date:11/28/2014)... "Most of my life, I have suffered from ... an inventor from Findlay, Ohio. "I thought that there had ... foot, which inspired me to invent this accessory." , She ... to support an injured foot. The sling makes it easier ... for crutches. The design redistributes weight so that the individual ...
(Date:11/28/2014)... TN (PRWEB) November 28, 2014 ARTAS ... Tennessee for the first time. PAI Medical Group hair ... will be performing a robotic hair transplant procedure in ... 9:00 A.M. , The first in Tennessee and one ... Medical Group now offers ARTAS robotic hair transplantation. Patients ...
(Date:11/28/2014)... Nipomo Family Dentistry , founded ... opened its doors at 195 N. Thompson St., Suite ... care like teeth cleanings, oral exams, fillings, implants and ... whitening (and Kor whitening), laser whitening, gum tissue treatment, ... Dentistry’s five-person team also takes a philanthropic approach to ...
Breaking Medicine News(10 mins):Health News:How Flu Vaccines Can Impact Families Is Discussed in New Article from Community Health Center of Snohomish County 2Health News:First in Tennessee - PAI Medical Group Announces ARTAS - The World’s Most Advanced Medical Robot Used for Hair Transplant Surgery 2Health News:Nipomo Family Dentistry Opens New Dental Office in Nipomo 2Health News:Nipomo Family Dentistry Opens New Dental Office in Nipomo 3
... choice of drug for patients suffering from prostate cancer may ... the Scottish Medicines Consortium (SMC) is of the view that ... much effect on prostate cancer making it an expensive not ... the drug feel that the drug had shown very good ...
... of the main causes of tooth loss worldwide and ... extractions (those with periodontal disease lost 2.8 teeth versus ... has now been found out from research that certain ... than others. ,The study analyzed the effects ...
... sinus tumors can be removed through the nose using endoscopy ... ,With this approach, doctors use tiny scopes and ... a device that pulverizes and suctions. At points where the ... and a diamond drill is used to eliminate tumor cells ...
... appears in the October issue of the journal ... early exposure to severe hypoglycemia during development negatively ... is a significant and relatively common complication of ... Repeated severe hypoglycemia has been reported to reduce ...
... Minister Anbumani Ramadoss has said that the government is very ... plans to take several steps to check female foeticide, which ... Ramadoss said that there were plans to set up surveillance ... practice that prevails on a large scale in the country. ...
... new research shows that in Children with neurological ... respiratory failure ,if they're hospitalized with influenza.// ... Journal of the American Medical Association, are based on ... influenza at The Children's Hospital of Philadelphia over four ...
Cached Medicine News:Health News:Nine Major Culprits For Tooth Loss Identified By Researchers 2Health News:Nine Major Culprits For Tooth Loss Identified By Researchers 3Health News:Novel Technique For Management Of Inverted Papilloma Of Frontal Sinus 2Health News:Severe Hypoglycemia And Spatial Memory In Children With Type 1 Diabetes 2
... WideBiter Punch series facilitates fast and effective ... smooth, anatomically shaped meniscal rim. The flat, ... to access even the tightest joint spaces. ... Inc., 20 years of engineering experience in ...
... fast and effective resection of meniscal tears ... rim. The flat, crescent-shaped tip has an ... tightest joint spaces. Made in the U.S. ... engineering experience in arthroscopy hand instrument design ...
... The WideBiter Punch series facilitates fast ... recreating a smooth, anatomically shaped meniscal rim. ... low profile to access even the tightest ... Arthrex California, Inc., 20 years of engineering ...
... The WideBiter Punch series facilitates fast ... recreating a smooth, anatomically shaped meniscal rim. ... low profile to access even the tightest ... Arthrex California, Inc., 20 years of engineering ...
Medicine Products: